Atlas Venture, one of the mainstay biotech venture capital firms, has collected its second batch of money within the past nine months.
Browsing: Market & Financials
Market trends, financial performance, quarterly results, and investment insights from global pharma and biotech companies.
Aurobindo Pharma invested USD 145 million in its China facility. • The plant commenced operations in November 2024. • Break-even at EBITDA level is expected by